<div id="readability-page-1"><p>Marex Group plc acquired a new position in shares of  Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 36,469 shares of the biotechnology company's stock, valued at approximately $576,000.</p><ul><li>Want Diversified Upside in Biotechnology? Check out LABU</li></ul><p>A number of other hedge funds also recently modified their holdings of the business. Virtus Advisers LLC purchased a new position in shares of  Arrowhead Pharmaceuticals during the second quarter valued at $34,000.  Nisa Investment Advisors LLC boosted its position in  Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,308 shares during the period.  Daiwa Securities Group Inc. boosted its position in  Arrowhead Pharmaceuticals by 883.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after acquiring an additional 3,763 shares during the period.  Mirae Asset Global Investments Co. Ltd. grew its stake in  Arrowhead Pharmaceuticals by 29.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after acquiring an additional 1,214 shares in the last quarter.  Finally, Lazard Asset Management LLC purchased a new stake in shares of  Arrowhead Pharmaceuticals in the second quarter worth approximately $91,000. Hedge funds and other institutional investors own  62.61% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of research analysts recently commented on the stock. Piper Sandler boosted their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, November 19th. Morgan Stanley boosted their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 26th. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Finally, Chardan Capital  reaffirmed a &#34;buy&#34; rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, five have assigned  a Buy rating, three have assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $58.56.</p><p><b>Check Out Our Latest Stock Analysis on Arrowhead Pharmaceuticals</b></p><h2>Arrowhead Pharmaceuticals Trading Down 1.0%</h2><p>Arrowhead Pharmaceuticals stock opened at $70.09 on Monday. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $72.36. The company's fifty day moving average price is $45.48 and its two-hundred day moving average price is $29.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of -876.02 and a beta of 1.28. </p><h2>Insider Activity at Arrowhead Pharmaceuticals</h2><p>In other news, Director Michael S. Perry sold 16,250 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a total value of $991,737.50. Following the completion of the sale, the director directly owned 115,240 shares in the company, valued at approximately $7,033,097.20. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Director Mauro Ferrari sold 8,750 shares of the firm's stock in a transaction on Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the completion of the transaction, the director owned 68,764 shares in the company, valued at $3,877,601.96. The trade was a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 45,000 shares of company stock valued at $2,185,150. Corporate insiders own  4.30% of the company's stock. </p><h2>About Arrowhead Pharmaceuticals</h2> (Free Report)<p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p><h2>Read More</h2><ul><li>Five stocks we like better than Arrowhead Pharmaceuticals</li><li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>Earnings Per Share Calculator: How to Calculate EPS</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>How to Profit From Value Investing </li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARWR

<p>Marex Group plc acquired 36,469 shares of Arrowhead Pharmaceuticals, Inc. during the 2nd quarter, valued at approximately $576,000. Several other hedge funds also modified their holdings in the company. Analysts have given Arrowhead Pharmaceuticals a 'Moderate Buy' rating with a consensus price target of $58.56. The stock opened at $70.09, with a market cap of $9.52 billion. Recent insider trading involved the sale of shares by directors Michael S. Perry and Mauro Ferrari.</p>

36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc